AgonOx partners with AstraZeneca unit for development of OX40 agonists in cancer therapy

2 November 2011

USA-based AgonOx has entered into an exclusive global partnership with MedImmune, the global biologics arm of Anglo-Swedish drug major AstraZeneca (LSE: AZN), to develop agonists using its OX40 platform.

MedImmune will lead further preclinical and clinical studies of this tumor-specific T-cell immunity stimulator for the potential treatment of cancer. Financial terms of the collaboration have not been disclosed.

"We are very pleased to collaborate with MedImmune to advance our OX40 agonist programs," said AgonOx chief executive Llew Keltner, noting that "MedImmune has impressive capabilities in immuno-oncology, and we believe offers great potential for eventually bringing therapies utilizing the OX40 mechanism to trigger tumor-specific immune responses to patients."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK